PURPOSE:: To investigate the efficacy and safety of fluocinolone acetonide intravitreal implant in patients with Vogt–Koyanagi–Harada disease. METHODS:: A post hoc, subgroup analysis on patients with Vogt–Koyanagi–Harada was performed using data sets from two multicenter randomized trials on fluocinolone acetonide implant. Each subject received fluocinolone acetonide implantation in one eye and standard-of-care treatment in the fellow eye and was followed for 3 years. RESULTS:: Thirty patients were included with the mean age of 38.5 years. The cumulative rate of uveitis recurrence for 3 years was significantly reduced in implanted eyes compared with fellow eyes (33 vs. 87%; P <0.001). The reduction of daily corticosteroid dose was well maintained (12.8 mg before implantation vs. 3.7 mg after implantation; P = 0.001), but final vision was similar to preoperative vision in the implanted eyes (P = 0.082) and in the fellow eyes (P = 0.187). Postoperative elevation of intraocular pressure was more frequent in the implanted eyes than in the fellow eyes (70 vs. 20%; P <0.001). Cataract progression occurred in all phakic implanted eyes. CONCLUSION:: Fluocinolone acetonide intravitreal implant reduced uveitis recurrence rate and the dosage of systemic corticosteroid and immunosuppressant requirement in patients with Vogt–Koyanagi–Harada. However, cataract and intraocular pressure elevation developed frequently.
ASJC Scopus subject areas